Black Phosphorus Quantum Dots Gated, Carbon-Coated Fe3 O4 Nanocapsules (BPQDs@ss-Fe3 O4 @C) with Low Premature Release Could Enable Imaging-Guided Cancer Combination Therapy.
Combination therapies for tumors based on different therapeutic approaches should try to improve treatment efficacy, but also to reduce side-effects related to the exogenous stimulus and premature release. In the following study, we established and validated a pH/near-infrared (NIR)/glutathione (GSH)/-responsive multifunctional disulfide cross-linked Fe3 O4 @C nanocarriers (ss-Fe3 O4 @C NCs) with black phosphorus quantum dots (BPQDs) as a capping agent. BPQDs and carbon shell of Fe3 O4 @C nanoparticles (NPs) were used as a photothermal agents, while the inner empty nucleus that allows for a high drug payload served as an effective drug carrier. These magnetofluorescent BPQDs@DOX@ss-Fe3 O4 @C NPs were conjugated with a targeting aptamer (epidermal growth factor receptor: EGFR), denoted as BPQDs@DOX@ss-Fe3 O4 @C-EGFR NPs, for targeting dual modal magnetic resonance (MR)/fluorescence imaging. The synthetic NCs showed that drug release was dependent on pH, near-infrared (NIR), and intracellular GSH levels, with minimum systemic release in the blood and maximum drug release within the tumors. Also, the photothermal effect resulting from the Fe3 O4 @C NPs and BPQDs upon application to NIR light caused a rapid rise in local temperature, which accounted for the highest enhancement of cell cytotoxicity. Thus, a theranostic system consisting of BPQDs@DOX@ss-Fe3 O4 @C-EGFR NPs is shown to generate excellent advantages in combined chemotherapy/photothermal therapy (PTT) with minimal side effects.